We have a team of experts with incredible knowledge and experience in a variety of backgrounds.
Board and Executive Management
XPhyto’s board and executive management bring significant expertise in science, therapeutics, business development and growth. Combine the collective skills of the team with an entrepreneurial eye for opportunity and you can see why XPhyto is poised to be a disrupter in the pharmaceutical industry.
Mr. Rogers is an entrepreneur and lawyer with private and public start-up experience in a range of industries and operational roles.
Recent advisory work has focused on public listings and corporate restructuring in the life science (cell therapy and medical device) and natural resource (natural gas co-gen and conventional oil) industries. Mr. Rogers has held several board and executive management positions with junior exchange listed issuers. He holds a bachelor’s degree in Cell Biology and Genetics and a Law degree. He is a member in good standing of the Law Society of British Columbia.
Prof. Dr. Thomas Beckert
Prof. Dr. Beckert is the founder, managing director, and qualified person of Vektor Pharma TF GmbH, Uttenweiler, Germany, and managing director of XP Diagnostics. He further is managing director of SCUR alpha 1108 GmbH, XPhyto’s holding company for the German operations.
Besides company organization, his expertise includes formulation and machine development for transdermal therapeutic systems and ODFs, narcotic drugs, cannabis, and herbal extracts in addition to global auditing of pharmaceutical suppliers (including cGMP, GDP, GACP, API, transdermals, solids, sterile dosage forms, analytical labs, microbiological labs, and pharmacovigilance).
Prof. Dr. Beckert passed his pharmaceutical state examination at the University of Freiburg, Freiburg im Breisgau, Germany in 1991, and holds a Ph.D. in Pharmacy from the University of Tübingen, Tübingen, Germany.
He was appointed professor of Pharmaceutical Process Technologies, University of Applied Sciences, Albstadt-Sigmaringen in 2020. From 1996 – 2009 he took the responsibility as a global technical customer advisor for EVONIK’s EUDRAGIT® product range for controlled drug delivery and was member of the board at Acino AG and Rentschler Pharma GmbH.
Mr. Roland Spleiss has joined as the Director of Business Development. Mr. Spleiss is a seasoned commercial professional with over 25 years of experience in planning and building out effective salesforces, strategic realignment, production relocation, and project management, which makes him ideally suited to drive product sales.
In addition to extensive consulting roles, Mr. Spleiss held senior positions including Chief Financial Officer of Wörwag Pharma, a private German health and generic pharmaceutical company with over EUR 200 million in annual sales and 900 employees. He led the company’s strategic professionalization and internationalization of operations, optimization of supply chains and sales processes, and expansion into new European, Asian and Latin American healthcare markets.
Mr. Spleiss’ expertise in production and supply chain management, cost optimization, and sales force and distribution network creation will be invaluable to XPhyto’s commercial strategy and execution.
Dr. Heinrich Jehle
Dr. Heinrich Jehle has joined XPhyto as Head of Diagnostic Research. Dr. Jehle has over 20 years’ experience in the research and development of innovative medical screening tests and diagnostics. Previously, Dr. Jehle held senior roles in project management and research & development at leading European biotech and diagnostics companies.
More recently, Dr. Jehle co-founded 3a-diagnostics GmbH as managing director where he led the development of the first saliva activated “in-mouth” biosensor candidates to identify active pathogens in the saliva and built a portfolio of innovative diagnostics biosensor products. The enzyme-activated biosensors are developed for real-time, low-cost and easy-to-use oral screening applications for the rapid detection of infectious diseases including COVID-19 at home or at the point-of-care.
Mr. Zdarek has over 25 years of European pharmaceutical sales and marketing success. His previous positions include over 13 years of marketing and sales for Teva Pharmaceutical focusing on the European market, Head of Business Development at CC Pharma GmbH and Head of Sales at Cell Pharma GmbH, a subsidiary of Stada Arzneimittel AG. Mr. Zdarek is a licensed pharmacist and a certified trainer for the Covid-ID Lab test.
Chartered Professional Accountant (CPA, CA) since 2008, obtained the Chartered Director (C.Dir.) designation from The Directors College (a joint venture between McMaster University and The Conference Board of Canada) in 2017. Joseph currently serves as the CFO for several publicly listed companies.
Mr. Thoresen is an experienced leader with an impressive track record in a wide range of executive management roles in the pharmaceutical industry. He has 25 years’ experience including executive roles with major international European and Asian-based pharmaceutical companies and has more recently led a number of successful ventures in the pharmaceutical manufacturing, nutraceutical and other industry sectors. From 2003 to 2014, Mr. Thoresen was the managing director of Nycomed Pharma AS acquired by Takeda Pharmaceutical Company Limited in 2011 as part of an acquisition transaction with a total value of approximately USD $14B.
Mr. Thoresen holds a law degree from the top-ranked University of Oslo and core competencies in strategy and organizational development, operational execution, and industry and government relations. He is an experienced chairman and board member of numerous European industry associations and companies and is the co-founder and current chairman of Curida AS, a Norwegian-based contract development manufacturing organization focused on liquid pharmaceutical production.
Prof. Dr. Raimar Löbenberg
Dr. Löbenberg holds a bachelor’s of Science degree in Pharmacy from the Johannes Gutenberg-University, Mainz, Germany and a PhD in Pharmaceutics from the Johann Wolfgang Goethe-University, Frankfurt, Germany. He joined the University of Alberta in 2000 where he is the founder and director of the Drug Development and Innovation Centre, Faculty of Pharmacy and Pharmaceutical Sciences. Dr. Löbenberg’s research interests are in biopharmaceutics to predict the oral performance of drugs and botanicals and inhalable nanoparticles to treat lung diseases such as lung cancer, tuberculosis or leishmanasis. He is a cofounder of RS Therapeutics Inc., a foam-based topical drug delivery company.
Dr. Löbenberg’s recent notable positions include: president of the Canadian Society for Pharmaceutical Sciences 2014 to 2015; vice chair of the United States Pharmacopeia Dietary Supplement Expert Committee 2016 to 2017; current member of the United States Pharmacopeia Dietary Supplement Expert Committee; current vice chair of the Specialty Committee of Traditional Chinese Medicine in Pharmaceutics of the World Foundation of Chinese Medicine Science; and current member of the Health Canada Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology and the Scientific Advisory Panel on Opioid Analgesic Abuse.
Mr. Probst is an experienced management consultant specialized in investment consulting and capitalization.
He’s an expert in mergers and acquisitions, corporate re-organizations, and divestitures and has adroitly brought multiple startups to success. Owing to his superior negotiating skills, he has a proven track record in strategic analysis, which resulted in highly targeted organizational restructuring.
Mr. Damouni is an entrepreneur and financier with over 18 years of experience in investment banking and capital markets including more than 10 years as a director or an officer of a number of private and public companies listed on the TSX, the TSXV and LSE.
Throughout his career, Mr. Damouni has taken a lead role in equity and debt financings.
His expertise on financing, restructuring, strategy development and execution, mergers and acquisitions has been instrumental in creating significant value for shareholders in the consumer, natural resources, technology and life sciences sectors.
To support XPhyto’s growth and expansion, we work with a team of advisors made up of leaders in their field who are passionate about XPhyto’s future and committed to our success.
For over 20 years, Adam has held numerous C-Level transformation and revenue growth leadership roles at multiple banks and technology firms. He is a board advisor to companies in FinTech, BioTech, Consumer Packaged Goods and AI and runs multiple Venture Capital and high yield growth funds. He specializes in revenue growth and M&A transaction advisory.
Adam’s primary experience has been in developing client-focused offerings rooted in technology. He has developed highly innovative front and back office solutions leveraging modern data and digital tools, processes partnerships and methodologies to push the envelope to challenge the status-quo.
Mr. Hughes was Chairman of a publicly listed cannabis company with operations in the most competitive cannabis market in the world, California. He raised C$27M, took the company public and delivered the construction of a 35,000 sqft premium indoor facility to production. He is an integrated marketing communications and innovations professional of 15+ years and has held board level positions for multiple companies and has success and experience in venture capital services and the commercialization of private and public companies across the globe: North America, Australia, and the Asia Pacific Region.
Dr. Allen Benson
Dr. Allen Benson, LLD is a member of the Beaver Lake First Nation. His life experience has fostered the development of strong family and community values: sharing, generosity and compassion for others which he has transformed into innovative service delivery, community-based action and a strong vision for the future of Aboriginal people. Mr. Benson has dedicated his life to advocating for the poor and disenfranchised and the actualization of healthy Aboriginal individuals, families and communities, both in Canada and internationally.
As the Chief Executive officer of Native Counselling Services of Alberta (NCSA), an agency that he has worked with for over 30 years, he has led NCSA in the development of many cutting edge programs for Aboriginal people, particularly in the areas of restorative and social justice, Aboriginal correctional services, health, housing, gang recruitment prevention/intervention and homelessness. He has also advanced the cause of Aboriginal control of community-based research and applied Aboriginal knowledge to current issues facing Aboriginal people.
Internationally, he works to achieve community-capacity building processes and structures to help Indigenous peoples to articulate and advance their visions for the future. While much of his work has focused on Aboriginal people, he also works tirelessly to use his experience and knowledge to develop the complementary partnerships that will create substantive change in both the Aboriginal and non-Aboriginal community. His accomplishments have been marked in such past rewards as the Alberta Centennial Medal, the Paul Harris Fellowship, the Edmonton and International Rotary Integrity Award, the Alberta Aboriginal Role Model Award in Justice, the DreamSpeakers Walk of Fame and an Honorary Doctorate from the University of Alberta.
Mr. Buchberger is an experienced leader in the medical and diagnostic products industry with an impressive track record.
For almost a decade, Mr. Buchberger was CEO and member of the Global Management Board of a medical and diagnostics product manufacturer with annual revenues of over €600 million.
He has many years of experience in international business development, sales, marketing, and product management and has successfully developed and managed business strategies and internationalization in Europe, North and South America, Middle East and Asia. Mr. Buchberger has been a key player in a wide range of successful global medical and diagnostic product launches.
“We have ambitious milestones for XPhyto’s future, and I am confident our team will execute.”
– Hugh Rogers, CEO